The effect of prasugrel on ADP-stimulated markers of platelet activation in patients with sickle cell disease

• Published in: Platelets (Edinburgh) Vol. 26; no. 5; pp. 474 - 479
• Main Authors: Jakubowski, Joseph A., Zhou, Chunmei, Winters, Kenneth J., Lachno, D. Richard, Howard, Jo, Payne, Christopher D., Mant, Timothy, Jurcevic, Stipo, Frelinger, Andrew L.
• Format: Journal Article
• Language: English
• Published: England Informa UK Ltd 04.07.2015; Taylor & Francis
• Subjects: Adenosine Diphosphate - metabolism; Adenosine Diphosphate - pharmacology; ADP; Adult; Anemia, Sickle Cell - blood; Anemia, Sickle Cell - drug therapy; Biomarkers; Blood Platelets - drug effects; Blood Platelets - metabolism; Case-Control Studies; Female; Humans; Leukocytes - drug effects; Leukocytes - metabolism; Male; Middle Aged; P2Y; Platelet Activation - drug effects; Platelet Aggregation Inhibitors - pharmacology; Platelet Aggregation Inhibitors - therapeutic use; platelets; prasugrel; Prasugrel Hydrochloride - pharmacology; Prasugrel Hydrochloride - therapeutic use; receptor antagonist; sickle cell disease; Young Adult; prasugrel; ADP; biomarkers; platelets; P2Y12 receptor antagonist; sickle cell disease

Abstract Platelets of patients with sickle cell disease (SCD) show evidence of mild activation in the non-crisis steady state and greater activation during vaso-occlusive crises (VOC). Prasugrel, a potent inhibitor of ADP-mediated platelet activation and aggregation, may be useful in attenuating VOC...